For most of the company’s history, UnitedHealth Group (UNH) has been a consistent winner. This blue-chip stock has long been favored by many risk-averse investors. However, the current market view on UnitedHealth is clearly divided.
According to 13F filings, in the first quarter of 2026, billionaires Chase Coleman and David Tepper both reduced their respective hedge funds’ holdings in UnitedHealth Group. At the same time, Wall Street analysts are generally bullish on the stock. This inevitably raises the question: Do Coleman and Tepper know something the market does not?
In the first quarter, Coleman’s Tiger Global Management hedge fund sold approximately 17% of its UnitedHealth stake, while Tepper’s Appaloosa hedge fund cut its position in the health insurance stock by 55%. Neither has publicly commented on the reasons for the reductions, but reasonable inferences can be drawn from external factors.
UnitedHealth Group faces more challenges now than when the two billionaires initially built their positions. The company’s medical costs are on the rise, squeezing profit margins. In addition, the future uncertainty surrounding Medicare Advantage reimbursement rates is greater than before. UnitedHealth is also facing an investigation by the U.S. Department of Justice.
However, Coleman and Tepper’s decisions to reduce their holdings may have nothing to do with these issues. They may simply be reallocating capital to other investments they believe offer greater growth potential. For example, both increased their holdings of semiconductor stocks in the first quarter.
Notably, these two billionaires were not the only ones reducing their UnitedHealth positions last quarter. Warren Buffett remains deeply involved in Berkshire Hathaway’s (BRKA) (BRKB) investment decisions, and the company liquidated its UnitedHealth stake in the first quarter. Yet this move may be part of a broader strategy to sell all stocks managed by Todd Combs, who left Berkshire to join JPMorgan Chase (JPM).
Among the 28 analysts covering UnitedHealth surveyed by S&P Global (SPGI) in May, 22 rated the stock as “Buy” or “Strong Buy,” five recommended “Hold,” and only one gave an “Underperform” rating.
Wall Street’s bullishness stems from the fact that UnitedHealth’s business is improving. The stock appears to be rebounding after a sharp decline last year. More importantly, Coleman and Tepper sold their shares before UnitedHealth released its first-quarter results in April 2026, and that earnings report was encouraging. UnitedHealth’s revenue and earnings easily surpassed analyst expectations. Notably, the company’s medical cost ratio fell 90 basis points to 83.9%, a figure better than expected and seemingly reflecting that UnitedHealth is effectively controlling its medical costs.
Both the billionaire hedge fund managers and Wall Street analysts may be correct in their assessments of UnitedHealth. Coleman and Tepper frequently move in and out of stocks, and their decisions to reduce holdings do not necessarily reflect a negative view of the company’s long-term prospects. Rather, they are focused on maximizing returns for their hedge funds, which sometimes means selling good stocks to invest in what they believe are even better alternatives.
